Zhang Xiao-Ying, Zhang Pei-Ying
Nanjing University of Chinese Medicine, Information Institute, Nanjing, Jiangsu 221009, P.R. China.
Department of Cardiology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China.
Oncol Lett. 2016 Dec;12(6):4297-4300. doi: 10.3892/ol.2016.5260. Epub 2016 Oct 13.
Hematological malignancies account for approximately 9.5% of new cancers diagnosed annually. Lymphoma is the most frequent of all known categories of hematological malignancies. Worldwide, extensive research has focused on this type of cancer. However, new treatments are investigated in various clinical as well as pre-clinical studies. Hematopoietic stem cell transplantation (HSCT) is a recent and upcoming treatment strategy for patients with hematopoietic malignancies and inborn errors of metabolism or immune deficiencies. Recent studies have revealed that successful clinical outcome of this treatment strategy depends on multiple factors including the protocol applied, disease under treatment, health of the patient, source of the grafts, severity of complications such as graft versus host disease during grafting and associated infections. The scope of this review is to achieve greater understanding of various clinical effects of the disease and related mechanisms. The electronic database Pubmed was searched for pre-clinical as well as clinical controlled trials reporting efficacy of the HSCT against hematological malignancies.
血液系统恶性肿瘤约占每年新诊断癌症的9.5%。淋巴瘤是所有已知血液系统恶性肿瘤类型中最常见的。在全球范围内，广泛的研究都集中在这类癌症上。然而，各种临床和临床前研究都在探索新的治疗方法。造血干细胞移植（HSCT）是一种针对造血系统恶性肿瘤、先天性代谢缺陷或免疫缺陷患者的最新且即将应用的治疗策略。最近的研究表明，这种治疗策略的成功临床结果取决于多个因素，包括所应用的方案、所治疗的疾病、患者的健康状况、移植物的来源、移植过程中移植物抗宿主病等并发症的严重程度以及相关感染。本综述的范围是更深入地了解该疾病的各种临床效应及相关机制。我们在电子数据库PubMed中搜索了关于HSCT治疗血液系统恶性肿瘤疗效的临床前及临床对照试验。
